Anti-thrombotic and Glucose Lowering Therapy in Diabetic Patients Undergoing PCI
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 1000
Summary
- Conditions
- Coronary Heart Disease
- Type2 Diabetes Mellitus
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Diabetes is one of the main risk factors for ischemic events in patients with coronary artery disease and diabetes is a factor in several post-PCI risk scores (including the commonly used DAPT score). However, until recently, there were almost no studies performed specifically in the diabetic popula...
Diabetes is one of the main risk factors for ischemic events in patients with coronary artery disease and diabetes is a factor in several post-PCI risk scores (including the commonly used DAPT score). However, until recently, there were almost no studies performed specifically in the diabetic population of patients undergoing PCI. At large, results from randomized trials assessing the duration of DAPT have produced conflicting results and there is uncertainty about the best anti-thrombotic strategy in patients with diabetes. Further assessment of the patterns of use and their clinical effects, including those related to prolonged DAPT is needed, in diabetic patients, especially in less selected "real world" populations.
Tracking Information
- NCT #
- NCT04481997
- Collaborators
- Cardiovascular Centre of the University of Lisbon (CCUL)
- AstraZeneca
- Investigators
- Principal Investigator: Sérgio B Baptista, PhD Cardiovascular Centre of the University of Lisbon (CCUL) Principal Investigator: Luís Raposo, MD Hospital de Santa Cruz, CHLO, EPE, Lisbon, Portugal